openPR Logo
Press release

Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

05-21-2025 01:42 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma

DelveInsight's, "Hunter Syndrome Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hunter Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hunter Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hunter Syndrome Pipeline. Dive into DelveInsight's comprehensive report today! @ Hunter Syndrome Pipeline Outlook [https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hunter Syndrome Pipeline Report

* In May 2025, Denali Therapeutics Inc . announced a Phase 2/3 study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).
* In May 2025, JCR Pharmaceuticals Co., Ltd. conducted a phase III study multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
* DelveInsight's Hunter Syndrome Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Hunter Syndrome treatment.
* The leading Hunter Syndrome Companies such as AVROBIO, Capsida Biotherapeutics, GENERIUM Pharmaceuticals, Denali Therapeutics, REGENXBIO, ArmaGen Technologies, Homology Medicines and others.
* Promising Hunter Syndrome Pipeline Therapies such as Elaprase, Idursulfase-IT, RGX-121, Hunterase, JR-141 and others.

Stay ahead with the most recent pipeline outlook for Hunter Syndrome. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hunter Syndrome Treatment Drugs [https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Hunter Syndrome Emerging Drugs Profile

* DNL310: Denali Therapeutics Inc

DNL310, or ETV:IDS, is a recombinant form of the iduronate 2-sulfatase ("IDS") enzyme engineered to cross the blood-brain barrier using Denali's proprietary ETV technology. DNL310 is intravenously administered and intended to improve overall clinical manifestations of Hunter Syndrome, including neurological symptoms, which are not adequately addressed by currently approved therapies. The FDA has granted orphan drug status and a rare pediatric disease designation to Denali Therapeutics pipeline candidate, DNL310. The drug is being evaluated in Phase I/II clinical trial to treat Hunter Syndrome.

* RGX-121: Regenxbio Inc.

RGX-121 is a product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome. RGX-121 is designed to use the AAV9 vector to deliver the human iduronate-2-sulfatase gene (IDS) which encodes the iduronate-2-sulfatase (I2S) enzyme to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted I2S beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 has received orphan drug product, rare pediatric disease and Fast Track designations from the U.S. Food and Drug Administration.

The Hunter Syndrome Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Hunter Syndrome with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hunter Syndrome Treatment.
* Hunter Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hunter Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hunter Syndrome market

Explore groundbreaking therapies and clinical trials in the Hunter Syndrome Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Hunter Syndrome Drugs [https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Hunter Syndrome Companies

AVROBIO, Capsida Biotherapeutics, GENERIUM Pharmaceuticals, Denali Therapeutics, REGENXBIO, ArmaGen Technologies, Homology Medicines and others.

Hunter Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Hunter Syndrome Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Unveil the future of Hunter Syndrome Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hunter Syndrome Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hunter Syndrome Pipeline Report

* Coverage- Global
* Hunter Syndrome Companies- AVROBIO, Capsida Biotherapeutics, GENERIUM Pharmaceuticals, Denali Therapeutics, REGENXBIO, ArmaGen Technologies, Homology Medicines and others.
* Hunter Syndrome Pipeline Therapies- Elaprase, Idursulfase-IT, RGX-121, Hunterase, JR-141 and others.
* Hunter Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hunter Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hunter Syndrome Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hunter Syndrome Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hunter-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Hunter Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* DNL310: Denali Therapeutics Inc
* Drug profiles in the detailed report.....
* Preclinical stage products
* AVR RD 05: AVROBIO
* Drug profiles in the detailed report.....
* Inactive Products
* Hunter Syndrome Key Companies
* Hunter Syndrome Key Products
* Hunter Syndrome- Unmet Needs
* Hunter Syndrome- Market Drivers and Barriers
* Hunter Syndrome- Future Perspectives and Conclusion
* Hunter Syndrome Analyst Views
* Hunter Syndrome Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hunter-syndrome-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hunter-syndrome-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here

News-ID: 4027006 • Views:

More Releases from ABNewswire

Afridi Legal & Financial Services Offers Professional Pashto, Urdu, Hindi, and English Interpretation Services Across Southern California
Afridi Legal & Financial Services Offers Professional Pashto, Urdu, Hindi, and E …
Image: https://www.abnewswire.com/upload/2025/10/843a0ff81e1c634385557fb28e3eb0a1.jpg Afridi Legal & Financial Services, operated by Shafi Afridi, provides professional interpretation services in Pashto Interpreter [https://www.afridi-document-preparer.com/interpretation-translation-services-pashto-urdu-hindi-english-southern-california.html], Urdu Interpreter [https://www.afridi-document-preparer.com/interpretation-translation-services-pashto-urdu-hindi-english-southern-california.html], and Hindi Interpreter [https://www.afridi-document-preparer.com/interpretation-translation-services-pashto-urdu-hindi-english-southern-california.html] languages throughout Southern California. With an A+ Better Business Bureau rating for over 15 years, the company has earned the trust of individuals, families, and small businesses seeking reliable, non-certified interpretation support across Orange, Los Angeles, Riverside, San Bernardino, Ventura, and San Diego Counties. Operating from
Lawrence Paulraj Announces the Release of His Debut Book, Building Things That Last
Lawrence Paulraj Announces the Release of His Debut Book, Building Things That L …
Lawrence Paulraj, Founder and CEO of LP Construction Group, has officially announced the upcoming release of his debut book, Building Things That Last. Set to launch at the end of 2025, the book is a great resource for individuals seeking to live with greater purpose and clarity of vision. Written from decades of personal and professional experience, Building Things That Last explores the essential role that vision plays in life. With
Jesus Empire Launches 4G/5G Mobile Proxies to Empower Safe, U.S.-Sourced Social Media Growth Campaigns
Jesus Empire Launches 4G/5G Mobile Proxies to Empower Safe, U.S.-Sourced Social …
Real rotating 4G/5G LTE IPs (U.S. only) for safer multi-account management, geo-targeting, and automated engagement Jesus Empire today announced the launch of Jesus Empire 4G/5G Mobile Proxies [https://jesusempire.com/jesus-empire-5g-mobile-proxies/], a next-generation proxy service providing real rotating U.S.-sourced 4G and 5G LTE IP addresses for creators, marketers, and automation agencies. By delivering genuine mobile IPs from U.S. carriers, Jesus Empire's proxies help clients scale social media campaigns with enhanced account safety, reduced ban
Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill Bacteria?
Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill …
Antibiotic resistance has become one of medicine's most urgent challenges. The CDC estimates that resistant infections cause ~35,000 deaths each year in the U.S. and more than 1 million globally - a number projected to rise sharply over the next 25 years. Traditional drug development is struggling to keep pace, forcing healthcare systems to look beyond antibiotics altogether. That search has reignited interest in a century-old idea that suddenly looks like

All 5 Releases


More Releases for Hunter

Hunter times Hunter Store unveils vibrant 2025 Summer Collection to delight glob …
The merch pays homage to Yoshihiro Togashi's masterpiece through high quality merch items Image: https://www.globalnewslines.com/uploads/2025/07/1401456a60e506ffd47129c404a6c133.jpg Hunter X Hunter Store [https://hunter-x-hunter.store/], the premier destination for fans of the renowned Hunter times Hunter manga and anime, has announced its all-new 2025 Summer Collection. Designed to celebrate the epic journeys, iconic characters, and dynamic Nen battles from Yoshihiro Togashi's masterpiece, this drop meets the merch demand of the series' worldwide fanbase-now totalling over 84 million
Hunter X Hunter Store Launches 2025 New Year Collection for Fans Worldwide
The new merch line is aimed at helping fans show their love for the beloved Shonen masterpiece. Image: https://www.globalnewslines.com/uploads/2025/01/babd1b7263365c868857d3d3a3f5841b.jpg Hunter X Hunter Store [https://hunter-x-hunter.store/], the ultimate hub for fans of Yoshihiro Togashi's iconic manga, has unveiled its highly anticipated 2025 New Year collection. This release pays homage to the legendary series, which has sold over 100 million copies globally thanks to its storytelling, unforgettable characters, and thrilling adventures. A spokesperson for Hunter X
Hunter Syndrome Treatment Market : An Overview
Introduction: Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. This deficiency leads to the accumulation of glycosaminoglycans in the body, resulting in a range of health complications, including developmental delays, skeletal deformities, and organ damage. The treatment for Hunter syndrome focuses on managing symptoms and improving the patient's quality of life. The Hunter syndrome treatment market has
Hunter x Hunter Store Launches New Global Collection for Fans of the Japanese ma …
The merch items help fans of the series show their love with high-quality and durable merch items. Image: https://www.getnews.info/uploads/8a9bc9d8c810ad4444dab5314a808bbd.png Hunter x Hunter Store [https://hunter-x-hunter.store/], the leading destination for fans of the manga series, has unveiled its latest collection of merch items. This trendy collection brings a range of new items that celebrate the rich history and beloved characters of the series. In a statement to the press, a senior representative for the online
Hunter Syndrome Treatment Market Size, Share | Hunter Syndrome Treatment Industr …
Global Hunter Syndrome Treatment Market Report provides a detailed industry overview along with the analysis of Cost Structure, Supply Chain, Development Techniques, Retailers Analysis, Financial Support, business Strategies, Marketing Channels. Global Hunter Syndrome Treatment Market research report provides a point-by-point In-Depth analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain
Hunter Syndrome Treatment Market Size, Share | Hunter Syndrome Treatment Industr …
Global Hunter Syndrome Treatment Market Report provides a detailed industry overview along with the analysis of Cost Structure, Supply Chain, Development Techniques, Retailers Analysis, Financial Support, business Strategies, Marketing Channels. Global Hunter Syndrome Treatment Market research report provides a point-by-point In-Depth analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain